There has been increasing interest in the development of strategies to enhance the number of CD34 + cells obtained during harvesting of peripheral blood progenitor cells (PBPC) to support high-dose chemotherapy. The strategies have included the use of chemotherapy plus cytokine for mobilization, and the development of more effective mobilizing cytokine combinations, such as stem cell factor plus filgrastim. Although there are costs associated with the implementation of these strategies, there are also predictable cost savings to be realized from the enhanced PBPC yields. Available data suggest that these cost savings include: $2000 per apheresis prevented, $6000 per back-up bone marrow harvest prevented, and at least $10 200 per remobilization and apheresis stage prevented. In addition, there is emerging evidence that the administration of optimal (у5 × 10 6 /kg) as opposed to acceptable but suboptimal (Ͼ1 × 10 6 /kg but Ͻ5 × 10 6 /kg) numbers of CD34 + PBPC will be associated with decreased supportive care needs and decreased costs of at least $4500-8000. These economic considerations should play a role, together with clinical data, in rational decision-making with respect to PBPC support.
recently led to an increasing use of PBPC in the setting of allogeneic transplantation.
The increased flexibility of PBPC in terms of the numbers of cells harvested and reinfused has made it important to explore issues surrounding the definition and measurement of PBPC graft quality. This is a rapidly evolving field. Table 1 lists current issues in PBPC graft quality. Most centers utilize the number of CD34
+ cells in the graft as the measure of its quality. However, there is also considerable interest in defining subsets of these CD34
+ cells based upon their expression of various differentiation markers that correlate better with either rapid or long-term engraftment. In the past, variations between centers in the methodology of CD34 + cell enumeration have led to variations in the number of CD34 + cells measured in a particular sample 11 and hence in the proposed optimal dose of CD34 + cells. This variation in methodologies of CD34 + cell enumeration slowed the development of standard definitions of graft quality. As enumeration methodologies become more standardized, variations across centers are diminished and standards are more consistent. Currently, most centers define 1 × 10 6 CD34 + cells per kilogram of body weight as the minimal number required to support HDC without obtaining additional progenitors either through BM harvesting or subsequent PBPC collection. Many centers identify 4 to 5 × 10 6 CD34 + cells/kg as the optimal number con- sistently associated with rapid engraftment, and try to obtain this target PBPC number whenever possible.
There are potential clinical advantages of PBPC harvests containing larger numbers of CD34 + cells. Several retrospective studies have examined the effects of achieving a threshold 'optimal' CD34 + cell dose on engraftment endpoints. [12] [13] [14] [15] [16] [17] These studies, utilizing threshold cell doses of 3 to 6.1 × 10 6 CD34 + cells/kg, have suggested that grafts above the threshold number are associated with decreases in the duration of thrombocytopenia, the number of platelet transfusions, and length of hospital stay. In addition, obtaining higher numbers of CD34 + cells increases the feasibility of both tandem high-dose chemotherapy treatments and ex vivo graft manipulations, including the various tumor cell purging processes that result in substantial losses of normal progenitor cells. These approaches to increasing the antitumor efficacy of HDC could potentially lead to improvements in survival, although this has not yet been demonstrated. Finally, there may be positive impacts of higher CD34
+ cell numbers on quality-of-life outcomes which remain to be identified and studied.
The recognition of the benefits of high CD34 + cell numbers has led to three main strategies to increase PBPC yield. The most frequently employed strategy involves the administration of a substantial dose of chemotherapy prior to the initiation of a mobilizing cytokine, with apheresis initiated when the white blood cell count has nadired and begun to rise. The chemotherapy-plus-cytokine strategy has been associated with greater numbers of CD34 + cells harvested in each apheresis session when compared to cytokine mobilization alone. 18 One theoretical advantage of this approach is the antitumor effect of the chemotherapy, although an impact on survival has not been demonstrated. Disadvantages have been the relatively high incidence of febrile neutropenia during the nadir and a decreased predictability of apheresis bed use, leading to inefficiencies for busy units.
A second approach is the utilization of cytokine combinations to enhance the numbers of CD34 + cells obtained in each apheresis. The most extensively studied combination has been filgrastim with stem cell factor (SCF), the ligand for the c-kit receptor. 19 This combination has been tested in several controlled clinical trials and has been shown to enhance apheresis yields in patients undergoing mobilization with cytokine alone, 20, 21 as well as in patients mobilized with chemotherapy plus cytokines. 22 Moreover, patients receiving the SCF/filgrastim combination have shown sustained CD34 + cell mobilization for up to 2 weeks, making prolonged daily harvesting feasible in patients who mobilize fewer PBPC on a daily basis. The IL-3 analogue daniplestim, in combination with filgrastim, has been shown to enhance CD34 + cell mobilization and apheresis yield, and has entered phase III studies. 23 Thrombopoietin with filgrastim has shown promise as a mobilizing combination in early phase I/II studies. 24 Preclinical studies have suggested that the flt-3 ligand in combination with myeloid growth factor may enhance PBPC mobilization. 25 A final strategy for increasing the number of PBPC has been the ex vivo expansion of these cells after harvesting. Of these three strategies, only chemotherapy/cytokine and cytokine combinations are currently feasible for the treatment of large numbers of HDC patients, and only cytokine combinations will be feasible for use in the allogeneic transplant setting.
Of the potential benefits of optimal CD34 + cell mobilization, three are expected to be associated with resource savings: (1) a decrease in the number of aphereses required to obtain an optimal or minimal number of cells; (2) a decreased need for back-up BM harvests or repeat mobilization to obtain a minimal number of CD34 + cells; and (3) more rapid and consistent hematopoietic recovery following HDC. Two benefits of enhanced CD34
+ cell harvests might be associated with improved cancer treatment outcomes and survival: (1) enhanced ability to carry out ex vivo manipulations of PBPC; and (2) enhanced feasibility of multicycle HDC procedures. This improved survival has not been demonstrated in studies to date, although it remains an area of considerable interest. Resource utilization is an important consideration in the provision of HDC services, given the current emphasis on cost containment and the trend toward case rates for reimbursement of HDC procedures. There are available data from which predictions of the cost effectiveness of enhanced CD34
+ cell mobilization can be derived. Figure 1 summarizes the economic considerations of strategies to increase the number of CD34 + PBPC harvested per apheresis. The most feasible strategies, chemotherapy with cytokines and cytokine combinations, both add to resource utilization during the mobilization phase of the patient's care. The magnitude of this increase has not been measured for chemotherapy plus cytokine compared to cytokine alone, and cost data are not yet available for the newer cytokines, such as SCF, which are used in the cytokine combinations. In determining the overall impact of a specific strategy on resource utilization, these cost increases during the mobilization phase should be balanced against resource savings during the apheresis and engraftment phases of the HDC procedure. As reviewed above, the potential cost savings include: (1) a decrease in the number of apheresis procedures required during the first apheresis phase; (2) a decrease in the number of second mobilization/apheresis procedures or back-up BM harvests required to supplement an unsuccessful first apheresis phase (ie in which the minimal number of CD34 + cells were not obtained); and (3) decreased utilization of supportive care services during the engraftment phase including days of hospital care, number of transfusions, and treatment with outpatient medications such as antibiotics and growth factors. Although further studies are required, cost estimates for each of these potential areas of cost savings are available and will be reviewed.
Economic considerations in PBPC graft optimization

The cost of apheresis
We estimated the cost of mobilization and apheresis of autologous PBPC in a study that relied on direct measurement of resources consumed rather than charges or charges modified using cost-to-charge ratios. 26 Patients in this study were undergoing mobilization with filgrastim alone at a + peripheral blood progenitor cells harvested in each apheresis session. The economic impact will depend upon the category of patient (see text), the institution's minimal requisite and optimal target CD34 + cell doses, and the institution's policy for obtaining additional progenitor cells from patients from whom minimal numbers of CD34 + cells are not obtained during the first apheresis stage. dose of 10 g/kg/day with apheresis beginning on day 5. Aphereses were performed using standard techniques, with 10 liters of blood processed during each session. We concluded that the cost for the first day of apheresis (including 5 days of filgrastim administration; catheter placement; 1 day of apheresis, processing, cryopreservation, and reinfusion of cells) cost the institution approximately $6200. Each additional day of apheresis (including one additional dose of filgrastim and an additional apheresis with processing and cryopreservation) was estimated to cost approximately $2000. These data indicate that any strategy that decreases the number of aphereses during the first apheresis stage would save approximately $2000 per prevented apheresis. Patients who fail to mobilize a minimal number of CD34 + cells during the first three or four aphereses are sometimes remobilized either because of BM involvement with tumor or due to institutional policy. Any strategy that decreases the need for remobilization would save at least $10 200, assuming that a cytokine-only mobilization regimen was used and a total of three aphereses were performed following remobilization. The predicted costs of remobilization would be higher with a chemotherapy/cytokine mobilization regimen, or if more than three aphereses were required.
The cost of bone marrow harvest
We have also estimated, using a resource-based costing methodology, the cost of BM harvesting. 26 The cost of harvesting, processing, cryopreserving, and reinfusing autologous BM was estimated to be approximately $5900. In most centers, patients who do not mobilize a minimal number of PBPC during the first apheresis phase and who do not have evident marrow involvement with tumor undergo BM harvesting to supplement the PBPC harvest. Any strategy that decreases the need for back-up BM harvesting would save approximately $5900 per procedure prevented.
The relationship of supportive care costs to the number of infused CD34
+ cells
Several studies have examined, in a retrospective fashion, the duration of thrombocytopenia and, in some studies, the number of platelet transfusions and length of hospital stay for patients undergoing HDC supported by PBPC either above or below a chosen CD34 + optimal threshold.
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These studies are summarized in Table 2 and, taken together, suggest that engraftment endpoints may be improved when optimal (ie above threshold) numbers of CD34 + cells are infused. Of these studies, four have given sufficient data to permit some estimate of the cost savings associated with a CD34 + cell dose of either 4 or 5 × 10 6 /kg compared with lower cell doses. 12, 13, 16, 17 A resource-based cost analysis has estimated that a platelet transfusion is associated with the consumption of resources costing approximately $671. 27 Using this estimate and the assumption that 1 hospital day is associated with an average cost of $1950 during the engraftment phase, 28 it is possible to estimate the supportive care cost savings for patients receiving optimal PBPC grafts. These estimates are summarized in Table 3 and suggest that the potential cost savings associated with optimal CD34 + cell dosing is between $6500 and $46 000. This wide range may relate to the prob- During a multicenter study in 203 patients with breast cancer undergoing HDC with PBPC support (cytokinealone mobilization, centralized CD34
+ cell enumeration), we collected hospital bills, transfusion data, and post-HDC filgrastim utilization and physician visit data in a prospective fashion. 28 Using an analysis based upon cost-to-charge ratios for hospital and transfusion costs and average wholesale price for outpatient filgrastim, we compared the post-HDC costs for patients receiving CD34
+ cell doses у5 × 10 6 /kg to those receiving Ͻ5 × 10 6 /kg but Ͼ1 × 10 6 /kg. In this study, mean costs were $4900 lower for patients receiving у5 × 10 6 /kg cell doses. On a multivariate analysis, at least $4350 of these cost savings were attributable to CD34 + cell dose alone, and were not explained by differences in age or prior chemotherapy. Data on outpatient medication use other than filgrastim and on utilization of home nursing services were not available, and it is likely that this figure is an underestimate of the actual impact of adequate but suboptimal, compared to optimal, CD34 + cell dosing on supportive care costs. In a multicenter study of 1774 patients with a variety of cancers undergoing chemotherapy plus cytokine mobilization and HDC, Weaver and colleagues 29 compared patients receiving a CD34 + cell dose у5 × 10 6 /kg to those receiving lower cell doses (median CD34 + cell dose in this group 3.5 × 10 6 /kg). Patients receiving the higher cell doses had significantly shorter duration of neutropenia and thrombocytopenia, fewer platelet and red cell transfusions, and shorter lengths of stay (mean 11 vs 14 days). Cost data were collected prospectively and patients receiving the higher CD34
+ cell dose had mean costs $8220 lower than patients in the below-threshold CD34 + dose group. These two prospective studies suggest that mean costs are lower by at least $4500 to $8000 for patients receiving optimal CD34 + cell doses, and that 5 × 10 6 CD34 + cells/kg is a reasonable optimal target dose.
Analysis of outliers vs measures of center
Medians are commonly employed in expressing engraftment data, both in the literature and in internal quality control procedures at centers providing HDC. An important shortcoming of this approach is that it is not sensitive to changes in the engraftment behavior of the last 10 to 25% of patients to engraft. There are data suggesting that differences in CD34 + cell dosing may have the greatest impact on this subset of patients, and that the proportion of patients who become engraftment outliers (with ongoing transfusion requirements and other supportive care needs for months following high-dose chemotherapy) may increase more rapidly than median engraftment times as the CD34 + cell dose is lowered. 3, 20 A disproportionate amount of health care resources are consumed by outliers, and reliance on measures of center in estimating the cost implications of engraftment data may result in a substantial underestimate of the cost impact of suboptimal CD34 + cell dosing. Figure 2 contains the Kaplan-Meier probability curves for platelet engraftment for 692 HDC patients divided by CD34 + cell doses into three groups: Ͻ5 × 10 6 /kg, 5-10 × 10 6 /kg, or Ͼ10 × 10 6 /kg. 13 These data indicate that when the CD34 + cell dose is Ͻ5 × 10 6 /kg, a significant probability exists that thrombocytopenia will persist for more than 30 days. By contrast, the median duration of thrombocytopenia is only slightly different for the three dose groups. Figure 3 shows a Cox proportional hazards model based upon data from 212 patients with breast cancer treated on a carefully controlled HDC protocol. 20 This model predicts that as the dose of CD34 + PBPC falls from 5 × 10 6 /kg to 1 × 10 6 /kg, the median time to platelet engraftment will remain at 14 days or less; however, the proportion of patients still requiring platelet transfusion on day 28 will rise from a negligible number to 20%. These studies indicate that a reliance on median engraftment data in analyzing the value of a given increase in CD34 + cell dose might lead to a conclusion that there is a small impact of dose on engraftment and hence costs. Based upon these data, a focus on outliers would alter this conclusion.
The contribution of the occasional outlier to the mean resource consumption measured in a particular study is one likely explanation for the wide ranges observed in the literature on this subject (Tables 2 and 3 ). These considerations strongly suggest that studies to date have underestimated the true cost impacts of lower CD34 + cell dose due to patient numbers insufficient to yield the statistical power necessary to accurately estimate the high cost of an increased proportion of outliers. Clearly, future studies of the cost impacts of higher CD34
+ cell doses should focus on mean as opposed to median resources consumed and should include sufficient numbers of patients to ensure that the contribution of outliers has been fully characterized.
Practical implications of the available economic data
The economic sequelae of strategies that increase CD34 + cell yields are likely to vary from patient to patient, but some generalizations by categories of patients are possible.
The 'good' mobilizer
In this category of patients, optimal numbers (ie 5 × 10 6 /kg) of CD34
+ cells are harvested during the first apheresis stage, although three to five aphereses may be required to achieve an optimal harvest. A representative group would be patients with stage II breast cancer. In this population of patients, the major impact of a superior mobilization strategy would be a decrease in the number of aphereses required, with a predicted cost savings of $2000 per apheresis prevented. The phase III study of SCF with filgrastim compared to filgrastim alone suggested that this strategy may decrease the number of requisite apheresis procedures by two. This would represent a predicted $4000 cost savings.
The 'fair' mobilizer
In this category of patients, adequate but suboptimal numbers (ie Ͼ1 × 10 6 /kg but Ͻ5 × 10 6 /kg) of CD34 + cells are harvested within the practical time frame of the first apheresis stage. Representative groups would be patients with multiple myeloma, lymphoma, and heavily pretreated metastatic breast cancer. In this population of patients, the major impact of a superior mobilization strategy would be an increase in the proportion of patients who receive an optimal graft, with predicted cost savings of $4500 to $8000 per patient in mean supportive care costs. As noted above, engraftment outliers consume large amounts of health care resources over a prolonged period of time. This resource utilization may be ongoing in some patients at the time that a resource utilization analysis is carried out; this has been one of the reasons that medians have been used more frequently than means in expressing engraftment data. Even when means are employed, data collection is frequently cut off at an arbitrary time point post-HDC despite ongoing resource consumption related to the procedure. Hence, the estimates above are likely to be lower than the true cost savings to be realized from outlier prevention.
The 'poor' mobilizer
In this category of patients, inadequate (ie Ͻ1 × 10 6 /kg) numbers of CD34 + cells are harvested during the first apheresis stage. These patients often have heavily pretreated lymphoma, although occasional patients in other groups are poor mobilizers. In most centers, these patients are subjected to either a second apheresis stage or a back-up BM harvest, depending upon marrow involvement, the yield of CD34 + cells during the first apheresis stage, and institutional policy. For these patients, the major impact of a superior mobilization regimen would be a decrease in the utilization of second apheresis stages or back-up BM harvests. This results in predicted savings of $6200 plus an additional $2000 for each day of apheresis following the first day per apheresis stage prevented, or $5900 per BM harvest prevented.
Cost-utility considerations
In some instances, the availability of a superior mobilization strategy may make HDC available to a patient who otherwise would not be eligible for HDC treatment. An example would be a patient with relapsed lymphoma with BM involvement from whom adequate numbers of PBPC cannot be obtained using standard techniques. Alternatively, a superior mobilization regimen may make tandem HDC treatments or ex vivo PBPC manipulation feasible. In these instances, the incremental expenses incurred in employing the strategy should be balanced against the demonstrated clinical benefits to the patients, such as survival or response duration, and not against cost savings during the engraftment phase.
Conclusion
With the realization of the clinical advantages of optimal CD34 + cell numbers in PBPC grafts, strategies for increasing the CD34 + cell yield of apheresis have emerged. In addition to the clinical benefits to patients undergoing HDC, good decision-making with respect to these emerging strategies should be based upon an understanding of their cost implications. The available data suggest that there are substantial cost savings to be realized for all categories of HDC patients when CD34
+ cell yield is enhanced. It is hoped that future studies will: (1) further document, prospectively, the independent effects of CD34 + cell dose on resource utilization; (2) better characterize the effects of CD34 + cell dose on engraftment outliers; and (3) assess the impact of CD34 + cell dose on nonhematopoietic endpoints including survival, quality of life, immune reconstitution, and tumor cell contamination.
